(17 intermediate revisions by 6 users not shown) | |||
Line 28: | Line 28: | ||
} | } | ||
− | |||
− | |||
− | |||
</style> | </style> | ||
Line 43: | Line 40: | ||
<div id="indexContent"> | <div id="indexContent"> | ||
<p><a href="#Reconnect" class="link">Reconnect Nerves</a></p> | <p><a href="#Reconnect" class="link">Reconnect Nerves</a></p> | ||
+ | <p><a href="#Cell" class="link">Cell culture</a></p> | ||
<p><a href="#Fight" class="link">Fight Infections</a></p> | <p><a href="#Fight" class="link">Fight Infections</a></p> | ||
<p><a href="#Kill" class="link">Kill Switch</a></p> | <p><a href="#Kill" class="link">Kill Switch</a></p> | ||
<p><a href="#Membrane" class="link">Membrane</a></p> | <p><a href="#Membrane" class="link">Membrane</a></p> | ||
− | |||
</div> | </div> | ||
<div id="indexRight"> | <div id="indexRight"> | ||
Line 167: | Line 164: | ||
</div> | </div> | ||
<p><i>Achievements: </i><br> | <p><i>Achievements: </i><br> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
− | <li>Successfully cloned a biobrick coding for secretion of NGF in pET43.1a and iGEM plasmid backbone pSB1C3, creating a new part <a href= | + | <li>Successfully cloned a biobrick coding for secretion of NGF in pET43.1a and iGEM plasmid backbone pSB1C3, creating a new part <a href="http://parts.igem.org/Part:BBa_K2616000"style="font-weight: bold ; color:#85196a;" target="__blank"> BBa_K2616000</a>. </li> |
− | <li>Successfully sequenced <a href= | + | <li>Successfully sequenced <a href="http://parts.igem.org/Part:BBa_K2616000"style="font-weight: bold ; color:#85196a;" target="__blank"> BBa_K2616000</a> BBa_K2616000</a> in pSB1C3 and sent to iGEM registry. </li> |
<li>Successfully co-transformed <i>E. coli</i> with plasmid secreting proNGF and plasmid expressing the secretion system, creating bacteria <b>capable of secreting NGF</b> in the medium.</li> | <li>Successfully co-transformed <i>E. coli</i> with plasmid secreting proNGF and plasmid expressing the secretion system, creating bacteria <b>capable of secreting NGF</b> in the medium.</li> | ||
<li>Successfully characterized production of proNGF thanks to mass spectrometry and western blot.</li> | <li>Successfully characterized production of proNGF thanks to mass spectrometry and western blot.</li> | ||
− | + | ||
− | + | ||
</ul><br></p> | </ul><br></p> | ||
<p><i>Next steps:</i><br> | <p><i>Next steps:</i><br> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li><b>Purify</b> secreted proNGF, and characterize its effects on neuron growth thanks to our microfluidic device. </li> | <li><b>Purify</b> secreted proNGF, and characterize its effects on neuron growth thanks to our microfluidic device. </li> | ||
− | + | ||
</ul> | </ul> | ||
</p> | </p> | ||
Line 187: | Line 183: | ||
<div class="block full bothContent"> | <div class="block full bothContent"> | ||
<div class="block dropDown" id="Cell"> | <div class="block dropDown" id="Cell"> | ||
− | <h4>CELL CULTURE<br><i>Click to see more</i></h4> | + | <h4>RECONNECT NERVES: CELL CULTURE<br><i>Click to see more</i></h4> |
</div> | </div> | ||
Line 200: | Line 196: | ||
<p><i>Imaging was performed in collaboration with the BioImagerie Photonique platform of the Institut Pasteur. Data are presented as MEAN ± SEM. Significance between 2 different groups was determined using an Ordinary one-way ANOVA test on the software Prism6 (GraphPad). (ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001) </i> </p> | <p><i>Imaging was performed in collaboration with the BioImagerie Photonique platform of the Institut Pasteur. Data are presented as MEAN ± SEM. Significance between 2 different groups was determined using an Ordinary one-way ANOVA test on the software Prism6 (GraphPad). (ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001) </i> </p> | ||
<p>As an alternative to our recombinant proNGF for control experiments, we performed an <i>in vitro</i> neural primary culture with commercial NGF. For this, a pair of E18 Sprague Dawley cortexes were purchased from BrainBits.co.uk. We digested the tissue with manufacturer provided papain according to their protocol and seeded 40 000 dissociated neurons on our microfluidic chips with different conditions of culture for six days at 37°C, and 5% CO2. </p> | <p>As an alternative to our recombinant proNGF for control experiments, we performed an <i>in vitro</i> neural primary culture with commercial NGF. For this, a pair of E18 Sprague Dawley cortexes were purchased from BrainBits.co.uk. We digested the tissue with manufacturer provided papain according to their protocol and seeded 40 000 dissociated neurons on our microfluidic chips with different conditions of culture for six days at 37°C, and 5% CO2. </p> | ||
+ | |||
<p>On our two-chamber microfluidic devices, we seeded neurons only on one side. Fifteen chips were used in total. After six days, neurons are fixed with paraformaldehyde (PFA) 4% and stained with DAPI. For differentiated markers: MAP2 (coupled with Alexa Fluor 555), a cytoskeletal associated protein and Beta-III Tubulin (coupled with Alexa Fluor 488), one of the major components of microtubules and a neuron-specific marker were used.</p> | <p>On our two-chamber microfluidic devices, we seeded neurons only on one side. Fifteen chips were used in total. After six days, neurons are fixed with paraformaldehyde (PFA) 4% and stained with DAPI. For differentiated markers: MAP2 (coupled with Alexa Fluor 555), a cytoskeletal associated protein and Beta-III Tubulin (coupled with Alexa Fluor 488), one of the major components of microtubules and a neuron-specific marker were used.</p> | ||
Line 209: | Line 206: | ||
<img src="https://static.igem.org/mediawiki/2018/4/43/T--Pasteur_Paris--Figure_11.png"> | <img src="https://static.igem.org/mediawiki/2018/4/43/T--Pasteur_Paris--Figure_11.png"> | ||
− | <div class="legend"><b>Figure 11: </b> In orange, are displayed bacteria found inside one of our microfluidic | + | <div class="legend"><b>Figure 11: </b> In orange, are displayed bacteria found inside one of our microfluidic devices.</div> |
</div> | </div> | ||
<br> | <br> | ||
Line 253: | Line 250: | ||
<div class="block full"> | <div class="block full"> | ||
− | <p>Because we were running out of fresh microfluidic chips, and since we already proved that our device was working as expected, we switched and put our next cultures in a 96-well plate for 10 days at 37°C, testing the influence of the different concentrations of NGF on the growth of the cells. </p> | + | <p>Because we were running out of fresh microfluidic chips, and since we already proved that our device was working as expected, we switched and put our next cultures in a 96-well plate for 10 days at 37°C, testing the influence of the different concentrations of NGF on the growth of the cells (Figure 14). </p> |
+ | </div> | ||
+ | <div class="block full"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/1/18/T--Pasteur_Paris--Figure_14_ABC.png"> | ||
+ | </div> | ||
+ | <div class="block full"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/c/c1/T--Pasteur_Paris--Figure_14_DEF.png"> | ||
</div> | </div> | ||
− | |||
<div class="legend"><b>Figure 14: </b> Best representations of the imaging of the 96-well plate for each condition. A2: 0 ng/mL commercial NGF, B3: 50 ng/mL commercial NGF, C4: 250 ng/mL commercial NGF, D4: 500 ng/mL commercial NGF, E4: 750 ng/mL commercial NGF, F4: 900 ng/mL commercial NGF. </div> | <div class="legend"><b>Figure 14: </b> Best representations of the imaging of the 96-well plate for each condition. A2: 0 ng/mL commercial NGF, B3: 50 ng/mL commercial NGF, C4: 250 ng/mL commercial NGF, D4: 500 ng/mL commercial NGF, E4: 750 ng/mL commercial NGF, F4: 900 ng/mL commercial NGF. </div> | ||
Line 262: | Line 264: | ||
</div> | </div> | ||
+ | <div class="block half"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/0/05/T--Pasteur_Paris--Figure_15_A.jpg"> | ||
+ | </div> | ||
+ | <div class="block half"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/c/cd/T--Pasteur_Paris--Figure_15_B.jpg"> | ||
+ | </div> | ||
<div class="block full"> | <div class="block full"> | ||
<div class="legend"><b>Figure 15: </b> <b>(A)</b> Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and <b>(B)</b> number of stained nuclei in each well with no NGF, 50 ng/mL, 250 ng/mL, 500 ng/mL, 750 ng/mL and 900 ng/mL of commercial NGF added in our medium Neurobasal, B27, GlutaMAX. Each condition was compared to the control group without NGF. <i>(ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001).</i></div> | <div class="legend"><b>Figure 15: </b> <b>(A)</b> Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and <b>(B)</b> number of stained nuclei in each well with no NGF, 50 ng/mL, 250 ng/mL, 500 ng/mL, 750 ng/mL and 900 ng/mL of commercial NGF added in our medium Neurobasal, B27, GlutaMAX. Each condition was compared to the control group without NGF. <i>(ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001).</i></div> | ||
Line 267: | Line 275: | ||
<div class="block full"> | <div class="block full"> | ||
− | <p>As we can see in Figure | + | <p>As we can see in Figure 15 <b>(A)</b>, it was possible to observe a difference in the percentage of area taken by the <FONT face="raleway">β</FONT>-III Tubulin. Indeed, it is possible to observe a significant increase in this percentage when commercial NGF is put at a concentration of 250 ng/mL or higher. The concentration of NGF seems to influence the growth of axons. It was possible to observe the same significant increase of cell number at a concentration of 250 ng/mL or higher (Figure 15 <b>B</b>). We can also see that at a concentration of 900 ng/mL, it seems that both the percentage of area taken by the <FONT face="raleway">β</FONT>-III Tubulin and the number of cells decrease, even though it is not significant, we can hypothesize that at a high concentration of NGF, the receptor p75<sup>NTR</sup> is getting internalized, resulting in a decreasing number of available receptors. </p> |
<p>It seems that commercial NGF has a dose-response effect on both the growth of neuronal axons and / or the survival of the cells. To determine in which category the NGF was affecting, we standardize the percentage area of <FONT face="raleway">β</FONT>-III Tubulin compared to the number of cells. </p> | <p>It seems that commercial NGF has a dose-response effect on both the growth of neuronal axons and / or the survival of the cells. To determine in which category the NGF was affecting, we standardize the percentage area of <FONT face="raleway">β</FONT>-III Tubulin compared to the number of cells. </p> | ||
Line 274: | Line 282: | ||
<div class="block full"> | <div class="block full"> | ||
− | + | <img src="https://static.igem.org/mediawiki/2018/6/6f/T--Pasteur_Paris--Figure_16.jpg" style="max-width:35em;"> | |
+ | </div> | ||
<div class="legend"><b>Figure 16:</b> Ratio of the percentage area of <FONT face="raleway">β</FONT>-III Tubulin on the number of stained nucleus. <i>(ns: non-significant, * : p<0.05, ** : p<0.01, *** : p<0.001, **** : p<0.0001).</i> </div> | <div class="legend"><b>Figure 16:</b> Ratio of the percentage area of <FONT face="raleway">β</FONT>-III Tubulin on the number of stained nucleus. <i>(ns: non-significant, * : p<0.05, ** : p<0.01, *** : p<0.001, **** : p<0.0001).</i> </div> | ||
− | |||
<div class="block full"> | <div class="block full"> | ||
− | <p>As we can see in figure | + | <p>As we can see in figure 16, we have a decreasing amount of <FONT face="raleway">β</FONT>-III Tubulin per nuclei each time the concentration of NGF gets higher. We can see a significant decrease of this ratio when the NGF is at 500 ng/mL and higher, which is not an expected result and an opposite result from the images that we occurred from the platform. </p> |
− | <p>We assumed from the start that all of our cells put in culture were neuronal cells, which might not be the case. We know that the NGF has an effect of the survival of the cells <sup>[1], [2]</sup> (Figure | + | <p>We assumed from the start that all of our cells put in culture were neuronal cells, which might not be the case. We know that the NGF has an effect of the survival of the cells <sup>[1], [2]</sup> (Figure 15 <b>B</b>). We did not have the suitable marker to differentiate the neuronal cells from the other types of cells, and should have stained the cells with NeuN, a neuronal nuclear antigen used as a biomarker for neurons. Therefore, the standardization we did with the number of cells is not an accurate one. We can still appreciate the qualitative results we had (Figure 14 and 15 <b>A</b>) and are positive on the effect NGF has on axon’s growth as well as cell survival.</p> |
− | <p>After having collected the data on the effect of commercial NGF, we decided to put in culture our cells in the presence of our bacterial lysate to test the effect of our proNGF. We put in culture for 2 days 30 000 cells with or without commercial NGF at 500 ng/mL and 900 ng/mL as well as our bacterial lysate in different dilutions. Since we wanted to inactivate as much bacterial proteins as possible ( | + | <p>After having collected the data on the effect of commercial NGF, we decided to put in culture our cells in the presence of our bacterial lysate to test the effect of our proNGF ( produced with <a href="http://parts.igem.org/Part:BBa_K2616000"> Bba_K2616000 </a> ). We put in culture for 2 days 30 000 cells with or without commercial NGF at 500 ng/mL and 900 ng/mL as well as our bacterial lysate in different dilutions. Since we wanted to inactivate as much bacterial proteins as possible (endotoxins), we checked the denaturation temperature for our proNGF, 70°C, and heat-inactivated the lysate at 60°C for 5 minutes before putting it in culture. Due to lack of time, only one well per condition was analyzed. </p> </div> |
− | <div class="block | + | <div class="block half"> |
+ | <img src="https://static.igem.org/mediawiki/2018/d/d1/T--Pasteur_Paris--Figure17A.jpg" style="max-width:30em;"></div> | ||
+ | <div class="block half"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/d/d1/T--Pasteur_Paris--Figure_17B.jpg"style="max-width:30em;"></div> | ||
− | <div class="legend"><b> Figure 17:</b> (A) Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and ( | + | <div class="legend"><b> Figure 17:</b> <b>(A)</b> Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and <b>(B)</b> percentage area of nucleus in each well with no commercial NGF, 500 ng/mL or 900 ng/mL or bacterial lysate at 1/5, 1/10, 1/20 or 1/30 added in our medium Neurobasal, B27, GlutaMAX. </div> |
− | |||
<div class="block full"> | <div class="block full"> | ||
− | <p>We can see in Figure | + | <p>We can see in Figure 17 that our lysate seems to increase the percentage area of the <FONT face="raleway">β</FONT>-III Tubulin compared to the control without NGF. Our results with the commercial NGF seem to be equivalent to the results we had from our first experiment (Figure 15), with a decrease of axons at a concentration of 900 ng/mL. We can hypothesize that the lysate does have an effect on axon’s growth from the increasing percentage area of <FONT face="raleway">β</FONT>-III Tubulin, increase similar to the one we observe in our first experiment (Figure 15) and that the activity of our proNGF could be equivalent to commercial NGF with a concentration between 500 ng/mL and 900 ng/mL.</p> |
− | <p>We also could see an influence of the commercial NGF on the survival of the cells, similar to our first experiment (Figure | + | <p>We also could see an influence of the commercial NGF on the survival of the cells, similar to our first experiment (Figure 15). Our lysate, put at a concentration of 1/10 and higher, seems to have the same effect (Figure 18). </p> |
</div> | </div> | ||
<div class="block full"> | <div class="block full"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/f/f1/T--Pasteur_Paris--Figure_18.jpg"style="max-width:50em;"></div> | ||
<div class="legend"><b>Figure 18: </b> Image of the whole well of the 96-well plate. Neurons were put in culture in Neurobasal, B27, GlutaMAX, and our lysate at a concentration of 1/10 medium.</div> | <div class="legend"><b>Figure 18: </b> Image of the whole well of the 96-well plate. Neurons were put in culture in Neurobasal, B27, GlutaMAX, and our lysate at a concentration of 1/10 medium.</div> | ||
− | + | ||
<div class="block full"> | <div class="block full"> | ||
Line 310: | Line 321: | ||
<div class="block title"><h1 id="References">REFERENCES</h1></div> | <div class="block title"><h1 id="References">REFERENCES</h1></div> | ||
<div class="block full"> | <div class="block full"> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li style="list-style-type: decimal;">Matsumoto, T., Numakawa, T., Yokomaku, D., Adachi, N., Yamagishi, S., | <li style="list-style-type: decimal;">Matsumoto, T., Numakawa, T., Yokomaku, D., Adachi, N., Yamagishi, S., | ||
Numakawa, Y., Kunugi, H., and Taguchi, T. (2006). <i>Brain-derived neurotrophicfactor-induced potentiation of glutamate and GABA release: Different dependency on signaling pathways and neuronal activity.</i>Mol. Cell. Neurosci. 31, 70–84 <br><br></li> | Numakawa, Y., Kunugi, H., and Taguchi, T. (2006). <i>Brain-derived neurotrophicfactor-induced potentiation of glutamate and GABA release: Different dependency on signaling pathways and neuronal activity.</i>Mol. Cell. Neurosci. 31, 70–84 <br><br></li> | ||
Line 317: | Line 328: | ||
</div> | </div> | ||
+ | |||
+ | <div class="block separator-mark"></div> | ||
+ | </div> | ||
+ | |||
+ | <div class="block full" style="background-color: transparent;"> | ||
+ | <div class="block title"> | ||
+ | <h3>Summary</h3> | ||
+ | </div> | ||
+ | <p><i>Achievements: </i><br> | ||
+ | <ul style="text-align: left;list-style: disc;"> | ||
+ | <li>Successfully <b>observed axon growth</b> in microfluidic chip in presence of commercial NGF.</li> | ||
+ | <li>Successfully observed <b>activity of our proNGF</b> in invitro cellular culture compared to commercial NGF with a concentration between 500 ng/mL and 900 ng/mL.</li> | ||
+ | </ul><br></p> | ||
+ | <p><i>Next steps:</i><br> | ||
+ | <ul style="text-align: left;list-style: disc;"> | ||
+ | <li><b>Statistical analysis</b> of our <i>in vitro</i> culture in presence of bacterial lysate. </li> | ||
+ | <li><b>Global proof of concept</b> in a microfluidic device containing neurons in one of the chamber, and our engineered bacteria in the other.</li> | ||
+ | |||
+ | </ul> | ||
+ | </p> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
</div> | </div> | ||
</div> | </div> | ||
Line 410: | Line 447: | ||
<div class="block one-third"> | <div class="block one-third"> | ||
<img src="https://static.igem.org/mediawiki/2018/f/f1/T--Pasteur_Paris--96-culture-wells-2.jpg"> | <img src="https://static.igem.org/mediawiki/2018/f/f1/T--Pasteur_Paris--96-culture-wells-2.jpg"> | ||
− | <div class="legend"><b>Figure 17: </b>Biofilm culture fixed with Bouin's solution in 96-well | + | <div class="legend"><b>Figure 17: </b>Biofilm culture fixed with Bouin's solution in 96-well microtiter plate</div> |
</div> | </div> | ||
Line 444: | Line 481: | ||
</div> | </div> | ||
<i><p>Achievements:<br></i> | <i><p>Achievements:<br></i> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li>Successfully cloned a biobrick coding for RIP secretion in pBR322 and in pSB1C3, creating a new part <a href="http://parts.igem.org/Part:BBa_K2616001"> Bba_K2616001 </a>. | <li>Successfully cloned a biobrick coding for RIP secretion in pBR322 and in pSB1C3, creating a new part <a href="http://parts.igem.org/Part:BBa_K2616001"> Bba_K2616001 </a>. | ||
<li>Successfully sequenced <a href="http://parts.igem.org/Part:BBa_K2616001"> Bba_K2616001 </a> in pSB1C3 and sent to iGEM registry. | <li>Successfully sequenced <a href="http://parts.igem.org/Part:BBa_K2616001"> Bba_K2616001 </a> in pSB1C3 and sent to iGEM registry. | ||
Line 450: | Line 487: | ||
</ul><br></p> | </ul><br></p> | ||
<p><i>Next steps:<br></i> | <p><i>Next steps:<br></i> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li>Clone the sensor device with inducible RIP production upon <i>S. aureus</i> detection.</li> | <li>Clone the sensor device with inducible RIP production upon <i>S. aureus</i> detection.</li> | ||
<li>Improve the characterization of RIP effect on biofilm formation with a more standardized assay.</li> | <li>Improve the characterization of RIP effect on biofilm formation with a more standardized assay.</li> | ||
Line 525: | Line 562: | ||
</div> | </div> | ||
<p><i><p>Achievements:<br></i> | <p><i><p>Achievements:<br></i> | ||
− | <ul style="text-align: left; | + | <ul style="text-align: left;list-style: disc;"> |
<li>Successfully cloned the biobrick <a href="http://parts.igem.org/Part:BBa_K2616002"style="font-weight: bold ; color:#85196a;"target="_blank"> Bba_K2616002</a> coding for toxin/antitoxin (CcdB/CcdA) system in pSB1C3, creating a <b>new part</b>.</li> | <li>Successfully cloned the biobrick <a href="http://parts.igem.org/Part:BBa_K2616002"style="font-weight: bold ; color:#85196a;"target="_blank"> Bba_K2616002</a> coding for toxin/antitoxin (CcdB/CcdA) system in pSB1C3, creating a <b>new part</b>.</li> | ||
<li>Successfully sequenced <a href="http://parts.igem.org/Part:BBa_K2616002"style="font-weight: bold ; color:#85196a;"target="_blank"> BBa_K2616002</a> in pSB1C3 and sent it to iGEM registry.</li> | <li>Successfully sequenced <a href="http://parts.igem.org/Part:BBa_K2616002"style="font-weight: bold ; color:#85196a;"target="_blank"> BBa_K2616002</a> in pSB1C3 and sent it to iGEM registry.</li> | ||
Line 531: | Line 568: | ||
</ul><br></p> | </ul><br></p> | ||
<p><i>Next steps:</i><br> | <p><i>Next steps:</i><br> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li>Find a system that kills bacteria when released in the environment rather than just stopping their growth.</li> | <li>Find a system that kills bacteria when released in the environment rather than just stopping their growth.</li> | ||
</ul> | </ul> | ||
Line 717: | Line 754: | ||
<div class="legend"><b>Figure 36: </b> Conductivity of a platinum wire for different frequencies (mean value and standard deviation for each membrane) </div> | <div class="legend"><b>Figure 36: </b> Conductivity of a platinum wire for different frequencies (mean value and standard deviation for each membrane) </div> | ||
<h4 style="text-align: left;"> Interpretation </h4> | <h4 style="text-align: left;"> Interpretation </h4> | ||
− | <p> Bare alumina oxide and PEDOT:PSS-coated membranes show similar | + | <p> Bare alumina oxide and PEDOT:PSS-coated membranes show similar conductivities, indicating the <b> incomplete coating of PEDOT:PSS </b> on alumina oxide membranes. On the opposite, PEDOT:Cl and PEDOT:Ts exhibit on average better conductivities, but in the same time, the coating of these membranes revealed by electron microscopy seemed to have covered the alumina oxide membranes in a more uniform way, <b> ensuring enhanced conductive capabilities </b>. These results can be criticized because of the high deviation and because the membranes conductivity was measured after several biofilms were grown on them, which may have affected the measurements. </p> |
</div> | </div> | ||
Line 753: | Line 790: | ||
</div> | </div> | ||
<p><i>Achievements: </i><br> | <p><i>Achievements: </i><br> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li> Successfully demonstrated the <b> confinement of bacteria </b> by a membrane filter. </li> | <li> Successfully demonstrated the <b> confinement of bacteria </b> by a membrane filter. </li> | ||
<li> Successfully <b> coated </b> alumina oxide membranes with PEDOT:Cl and PEDOT:Ts .</li> | <li> Successfully <b> coated </b> alumina oxide membranes with PEDOT:Cl and PEDOT:Ts .</li> | ||
Line 760: | Line 797: | ||
<li> Successfully <b> enhanced biocompatibilty </b> with PEDOT:Cl coating. </li></ul><br></p> | <li> Successfully <b> enhanced biocompatibilty </b> with PEDOT:Cl coating. </li></ul><br></p> | ||
<p><i>Next steps:</i><br> | <p><i>Next steps:</i><br> | ||
− | <ul style="text-align: left;"> | + | <ul style="text-align: left;list-style: disc;"> |
<li> Enhance <b> measurement precision </b> for membrane conductivity with and without biofilm.</li> | <li> Enhance <b> measurement precision </b> for membrane conductivity with and without biofilm.</li> | ||
<li> Improve <b> PEDOT:PSS coating </b> to form a uniform layer.</li> | <li> Improve <b> PEDOT:PSS coating </b> to form a uniform layer.</li> |
Latest revision as of 14:55, 10 November 2018
RECONNECT NERVES: DNA ASSEMBLY
Click to see more
Summary
Achievements:
- Successfully cloned a biobrick coding for secretion of NGF in pET43.1a and iGEM plasmid backbone pSB1C3, creating a new part BBa_K2616000.
- Successfully sequenced BBa_K2616000 BBa_K2616000 in pSB1C3 and sent to iGEM registry.
- Successfully co-transformed E. coli with plasmid secreting proNGF and plasmid expressing the secretion system, creating bacteria capable of secreting NGF in the medium.
- Successfully characterized production of proNGF thanks to mass spectrometry and western blot.
Next steps:
- Purify secreted proNGF, and characterize its effects on neuron growth thanks to our microfluidic device.
RECONNECT NERVES: CELL CULTURE
Click to see more
Summary
Achievements:
- Successfully observed axon growth in microfluidic chip in presence of commercial NGF.
- Successfully observed activity of our proNGF in invitro cellular culture compared to commercial NGF with a concentration between 500 ng/mL and 900 ng/mL.
Next steps:
- Statistical analysis of our in vitro culture in presence of bacterial lysate.
- Global proof of concept in a microfluidic device containing neurons in one of the chamber, and our engineered bacteria in the other.
FIGHT INFECTIONS
Click to see more
Summary
Achievements:
- Successfully cloned a biobrick coding for RIP secretion in pBR322 and in pSB1C3, creating a new part Bba_K2616001 .
- Successfully sequenced Bba_K2616001 in pSB1C3 and sent to iGEM registry.
- Successfully cultivated S. aureus biofilms in 96-well plates with different supernatants. Although there was a high variability in our results, and we used several protocols to overcome it, in one case, we were able to observe a reduction in biofilm formation in the presence of our RIP.
Next steps:
- Clone the sensor device with inducible RIP production upon S. aureus detection.
- Improve the characterization of RIP effect on biofilm formation with a more standardized assay.
KILL SWITCH
Click to see more
Summary
Achievements:
- Successfully cloned the biobrick Bba_K2616002 coding for toxin/antitoxin (CcdB/CcdA) system in pSB1C3, creating a new part.
- Successfully sequenced BBa_K2616002 in pSB1C3 and sent it to iGEM registry.
- Successfully observed normal growth of our engineered bacteria at 25°C and 37°C and absence of growth at 18°C and 20°C, showing the efficiency of the kill switch.
Next steps:
- Find a system that kills bacteria when released in the environment rather than just stopping their growth.
MEMBRANE
Click to see more
Summary
Achievements:
- Successfully demonstrated the confinement of bacteria by a membrane filter.
- Successfully coated alumina oxide membranes with PEDOT:Cl and PEDOT:Ts .
- Partially coated alumina oxide membranes with PEDOT:PSS.
- Successfully demonstrated the enhanced conductivity induced by the PEDOT:Cl and PEDOT:Ts coating.
- Successfully enhanced biocompatibilty with PEDOT:Cl coating.
Next steps:
- Enhance measurement precision for membrane conductivity with and without biofilm.
- Improve PEDOT:PSS coating to form a uniform layer.